肺孢子菌肺炎诊治的研究进展

摘要/Abstract

摘要：

目的综述肺孢子菌肺炎（PCP）病原诊断和治疗的研究进展。方法通过文献检索和分析，总结PCP诊治研究进展。结果 PCP的临床诊断主要依据患者存在免疫缺陷或免疫功能低下的基础状况以及典型临床和影像学表现来进行，确诊有赖于病原学检查。近年来研究表明PCR技术和血清1，3-β-D葡聚糖检测（G试验）有助于PCP早期诊断以及区分肺孢子菌定植和感染。复方磺胺甲噁唑（SMZco）是治疗PCP的首选用药，卡泊芬净近年来也联合应用于PCP的治疗，但其应用价值仍待进一步研究。结论 PCP的诊断仍以临床诊断为主，治疗上仍以SMZco为首选，探索PCP早期诊断技术和提高重症患者救治成功率是今后研究的重点。

关键词: 肺孢子菌肺炎, 诊断, 治疗

Abstract:

Objective To review the progress in the diagnosis and treatment of Pneumocystis pneumoniae (PCP). Methods The progress of PCP diagnosis and treatment was summarized by literature retrieving and analyzing literature. Results The clinical diagnosis of PCP is mainly based on the basic condition of immunodeficiency or immune suppression, and typical clinical and imaging manifestations, and the definite diagnosis depends on etiological examination. In recent years, many studies have shown that PCR and serum (1,3)-beta-D-glucan assay are helpful to the early diagnosis of PCP and to distinguish colonization and infection of Pneumocystis. Compound sulfamethoxazole (SMZco) is the preferred drug for the treatment of PCP, in addition, caspofungin was combined with SMZco to treat PCP in recent years, but its value in PCP treatment remains to be further studied. Conclusion The diagnosis of PCP mainly depends on clinical presentations. SMZco is the first choice for PCP treatment. Exploring the early diagnosis technology of PCP and improving the success rate of critical cases is the focus of future research.

Key words: Pneumocystis pneumonia, diagnosis, treatment

中图分类号:

R519

何小清, 沈银忠. 肺孢子菌肺炎诊治的研究进展[J]. 中国真菌学杂志, 2018, 13(4): 247-251.

HE Xiao-qing, SHEN Yin-zhong. Research progress in the diagnosis and treatment of Pneumocystis pneumonia[J]. Chinese Journal of Mycology, 2018, 13(4): 247-251.

参考文献

[1] Rostved AA, Sassi M, Kurtzhals JA, et al. Outbreak of Pneumocystis pneumonia in renal and liver transplant patients caused by genotypically distinct strains of Pneumocystis jirovecii[J]. Transplantation, 2013,96(9):834-842.
[2] 赵铁梅, 佘丹阳, 解立新, 等. 非艾滋病免疫功能抑制患者肺孢子菌肺炎的临床特点及诊治探讨[J]. 中华医院感染学杂志, 2014(06):1384-1386.
[3] Lu JJ, Lee CH. Pneumocystis pneumonia[J]. J Formos Med Assoc, 2008,107(11):830-842.
[4] Esteves F, Cale SS, Badura R, et al. Diagnosis of Pneumocystis pneumonia:evaluation of four serologic biomarkers[J]. Clin Microbiol Infect, 2015,21(4):371-379.
[5] Ebner L, Walti LN, Rauch A, et al. Clinical course, radiological manifestations, and outcome of Pneumocystis jirovecii pneumonia in HIV patients and renal transplant recipients[J]. PLoS One, 2016,11(11):e164320.
[6] Kaur R, Katariya P, Dhakad MS, et al. An unusual case of cystic fibrosis associated Pneumocystis jiroveci pneumonia in an infant[J]. Case Rep Infect Dis, 2016,2016:9206707.
[7] 鲁怀伟, 胡晓文, 徐傲, 等. 不同染色方法对肺孢子菌的诊断作用比较[J]. 临床输血与检验, 2012(02):147-148.
[8] Robberts FJ, Liebowitz LD, Chalkley LJ. Polymerase chain reaction detection of Pneumocystis jiroveci:evaluation of 9 assays[J]. Diagn Microbiol Infect Dis, 2007,58(4):385-392.
[9] Fan LC, Lu HW, Cheng KB, et al. Evaluation of PCR in bronchoalveolar lavage fluid for diagnosis of Pneumocystis jirovecii pneumonia:a bivariate meta-analysis and systematic review[J]. PLoS One, 2013,8(9):e73099.
[10] Izadi M, Jonaidi JN, Sadraei J, et al. The prevalence of Pneumocystis jiroveci in bronchoalveolar lavage specimens of lung transplant recipients examined by the nested PCR[J]. Jundishapur J Microbiol, 2014,7(12):e13518.
[11] Santos CR, de Assis AM, Luz EA, et al. Detection of Pneumocystis jirovecii by nested PCR in HIV-negative patients with pulmonary disease[J]. Rev Iberoam Micol, 2017,34(2):83-88.
[12] Damiani C, Le Gal S, Da CC, et al. Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1->3)-beta-D-glucan for differential diagnosis of Pneumocystis pneumonia and Pneumocystis colonization[J]. J Clin Microbiol, 2013,51(10):3380-3388.
[13] Kutty G, Shroff R, Kovacs JA. Characterization of Pneumocystis major surface glycoprotein gene (msg) promoter activity in Saccharomyces cerevisiae[J]. Eukaryot Cell, 2013,12(10):1349-1355.
[14] Lahmer T, Da CC, Held J, et al. Usefulness of 1,3 Beta-D-glucan detection in non-HIV immunocompromised mechanical ventilated critically ill patients with ARDS and suspected Pneumocystis jirovecii pneumonia[J]. Mycopathologia, 2017,182(7-8):701-708.
[15] Kamada T, Furuta K, Tomioka H. Pneumocystis pneumonia associated with human immunodeficiency virus infection without elevated (1-> 3)-beta-D glucan:a case report[J]. Respir Med Case Rep, 2016,18:73-75.
[16] Tasaka S, Kobayashi S, Yagi K, et al. Serum (1-> 3) beta-D-glucan assay for discrimination between Pneumocystis jirovecii pneumonia and colonization[J]. J Infect Chemother, 2014,20(11):678-681.
[17] Vogel M, Weissgerber P, Goeppert B, et al. Accuracy of serum LDH elevation for the diagnosis of Pneumocystis jiroveci pneumonia[J]. Swiss Med Wkly, 2011,141:w13184.
[18] Esteves F, Lee CH, de Sousa B, et al. (1-3)-beta-D-glucan in association with lactate dehydrogenase as biomarkers of Pneumocystis pneumonia (PcP) in HIV-infected patients[J]. Eur J Clin Microbiol Infect Dis, 2014,33(7):1173-1180.
[19] Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children:recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics[J]. MMWR Recomm Rep, 2009,58(RR-11):1-166.
[20] Miller RF, Huang L, Walzer PD. Pneumocystis pneumonia associated with human immunodeficiency virus[J]. Clin Chest Med, 2013,34(2):229-241.
[21] Chang HM, Tsai HC, Lee SS, et al. High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with Pneumocystis pneumonia and AIDS[J]. J Chin Med Assoc, 2016,79(6):314-319.
[22] Suarez I, Roderus L, van Gumpel E, et al. Low prevalence of DHFR and DHPS mutations in Pneumocystis jirovecii strains obtained from a German cohort[J]. Infection, 2017,45(3):341-347.
[23] Ponce CA, Chabe M, George C, et al. High Prevalence of Pneumocystis jirovecii dihydropteroate synthase gene nutations in patients with a first episode of Pneumocystis pneumonia in Santiago, Chile, and clinical response to trimethoprim-sulfamethoxazole therapy[J]. Antimicrob Agents Chemother, 2017,61(2):e1216-e1290.
[24] Cushion MT, Collins MS. Susceptibility of Pneumocystis to echinocandins in suspension and biofilm cultures[J]. Antimicrob Agents Chemother, 2011,55(10):4513-4518.
[25] Maschmeyer G, Helweg-Larsen J, Pagano L, et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients[J]. J Antimicrob Chemother, 2016,71(9):2405-2413.
[26] Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents:recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America[J]. MMWR Recomm Rep, 2009,58(RR-4):1-207, E1-E4.
[27] 中华医学会感染病学分会艾滋病学组.艾滋病诊疗指南第三版(2015版)[J]. 中华临床感染病杂志, 2015,8(5):385-401.
[28] Solodokin LJ, Klejmont LM, Scipione MR, et al. Safety and effectiveness of intravenous pentamidine for prophylaxis of Pneumocystis jirovecii pneumonia in pediatric hematology/oncology patients[J]. J Pediatr Hematol Oncol, 2016,38(6):e180-e185.
[29] 刘文杰, 赵明. 小剂量复方磺胺甲噁唑预防肾移植后肺孢子菌肺炎[J]. 中国组织工程研究, 2012(40):7421-7425.